Clinical Trials Directory

Trials / Conditions / Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

9 registered clinical trials studyying Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia — 3 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects
NCT06927466
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.Phase 1
RecruitingA Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lym
NCT06173518
Autolus LimitedPhase 1
UnknownCD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malig
NCT05105867
920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaEARLY_Phase 1
RecruitingCART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Ly
NCT05054257
Institute of Hematology and Blood Transfusion, Czech RepublicPhase 1
Active Not RecruitingBAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
NCT04690595
PeproMene Bio, Inc.Phase 1
Active Not RecruitingA Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphob
NCT04404660
Autolus LimitedPhase 1 / Phase 2
TerminatedCD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL
NCT04034446
Institute of Hematology & Blood Diseases Hospital, ChinaEARLY_Phase 1
TerminatedPilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy
NCT02588456
University of PennsylvaniaPhase 1
WithdrawnDose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
NCT02215629
Verastem, Inc.Phase 1